Navigation Links
Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
Date:2/18/2009

son's risk of developing chronic liver disease, cirrhosis, liver cancer and death.

Liver disease associated with HCV infection is growing rapidly, and current therapies only provide sustained benefit in about half of patients with the genotype 1 form of the virus. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best-in- class small molecule drugs in the anti-infective field. Enanta is developing novel protease, polymerase and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections and intravenous and oral treatments for hospital and community MRSA. Enanta is a privately held company headquartered in Watertown, Mass. Enanta's news releases and other information are available on the company's web site at http://www.enanta.com.

About Abbott

Abbott is working to advance the treatment of Hepatitis C (HCV) through a multifaceted discovery and development program that leverages the company's deep experience in antiviral medicines. Compounds in various states of development include protease inhibitors (ABT-450) and polymerase inhibitors (ABT-333 and ABT-072). In addition to developing HCV therapies, Abbott also offers laboratory tests for patient diagnosis, blood screening tests for hospitals and blood banks, and molecular diagnostic tests to measure HCV viral load and resistance.

Abbott is a global
'/>"/>

SOURCE Abbott; Enanta Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
2. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
3. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
4. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
5. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
6. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
7. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
8. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
9. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Techpool Bio-Pharma Co has experienced tremendous ... its new chief executive officer, transforming from a traditional private ... Henry Lee took office in 2011, he was the ... including Novartis and Eisai, with more than 20 years successful ... the Asia-Pacific region. "I ...
(Date:4/27/2015)... Ga., April 27, 2015  MiMedx Group, Inc. ... company utilizing human amniotic tissue and patent-protected processes ... for the Wound Care, Surgical, Orthopedic, Spine, Sports ... today its record results for the first quarter ... announced today the decision of its Board of ...
(Date:4/27/2015)... April 27, 2015  Consumer Watchdog today applauded ... that requires prescribers to check a state database ... OxyContin and other opioids – to help prevent ... SB 482, authored by Sen. ... , will require prescribers to check Controlled Substance ...
Breaking Medicine Technology:Techpool Transforms Into International Player 2Techpool Transforms Into International Player 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 2MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 4MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 5MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 6MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 7MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 8MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 9MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 10MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 11MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 12MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 13MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 14Consumer Watchdog Praises Passage of Bill that Requires Physicians Check Prescription Drug Database Before Prescribing Powerful, Addictive Medications 2Consumer Watchdog Praises Passage of Bill that Requires Physicians Check Prescription Drug Database Before Prescribing Powerful, Addictive Medications 3
... Therapeutics, Inc. (Nasdaq: OREX ) today announced the ... consisted of one share of common stock and a warrant ... to the public of $1.45 per share of common stock ... stock, which together comprised the purchase price of $15.94 per ...
... organizations, community leaders, health care professionals, and people of ... today urged Express Scripts to get back to the ... access to pharmacy services for hundreds of millions of ... put the people of our communities at the forefront ...
Cached Medicine Technology:Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock 2Over 130 Community Leaders and Organizations Across the Nation Urge Express Scripts To Reach Agreement With Walgreens 2
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable ... and Fashion Show from 10:30 a.m. to noon on ... 2626 W. 63rd St. in Chicago, serves low-income older ... to maintain their independence. , “Mothers, grandmothers, godmothers and ... Day Brunch,” said Director of Marketing Elizabeth Clippard. , ...
(Date:4/27/2015)... Church, VA (PRWEB) April 28, 2015 ... Works, **Presented by FDAnews and Ombu Enterprises**, June 16-17, ... If an FDA inspector came to a facility today, ... , If the answer is "maybe" or "no" ... Ombu Enterprises and FDAnews have a solution. , ...
(Date:4/27/2015)... 2015 How to Implement UDI:, Lessons ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI ... of regulatory restraint, there’s plenty of time to get ... again. UDI deadlines are coming fast for all devicemakers ... Don’t delay, even if it seems there’s no rush. ...
(Date:4/27/2015)... April 28, 2015 Healthcare marketing ... paper called “Website Anatomy 101.” Available ... the necessary design elements for a successful hospital ... responsive design, user experience, search results and lead ... of a well-designed website on patient volume and ...
(Date:4/27/2015)... 2015 Women may have a more ... to a new study published online in the journal ... injury (MTBI), is a common medical problem affecting cognitive ... , In most cases, patients who experience MTBI will ... percent of MTBI patients will continue to experience persistent ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
... 3 America,s oldest voluntary health organization is led ... Elected National Board Chair, after more than a decade ... successfully steered the American Lung Association to tackle key ... of his chairmanship has been to build on the ...
... variation in exposure, depending on several factors, , , TUESDAY, ... widely among people who undergo computed tomography (CT) scans, ... in the Feb. 4 issue of the Journal ... after the American Heart Association urged that CT scans ...
... for Southeastern Michigan Screens Patients DETROIT, Feb. 3 ... Saturday, February 7, over 300 children from the Detroit ... of the American Dental Association,s seventh annual "Give Kids ... their services that day to children who, because of ...
... Reinforce Commitment to Safety Net Partnerships and Quality ... Kaiser Permanente announced today that ... totaling approximately $43 million in the fourth quarter ... Community Benefit grants in the fourth quarter focused ...
... Feb. 3 Nearly three out ... insurance should cover the cost of addiction treatment ... their own health insurance would pay for substance ... Toward Addiction Survey" from Hazelden, the national nonprofit ...
... NASHVILLE, Tenn., Feb. 3 Healthcare Realty Trust,Incorporated (NYSE: ... cash dividend for the,quarter ended December 31, 2008. ... payable on March 5, 2009 to shareholders of record ... Realty Trust is a real estate investment trust that ...
Cached Medicine News:Health News:Maryland Lawyer Steve Nolan Advocates for Lung Health as National Board Chair of the American Lung Association 2Health News:Radiation From CT Scans Not Always the Same 2Health News:Radiation From CT Scans Not Always the Same 3Health News:Area Dentists, University of Detroit Mercy Team Up to Provide Free Dental Care to Low-Income, Uninsured Detroit-Area Children on Saturday, February 7 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 3Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 4Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: